Nedosiran

• Description :

  Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH) . Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD) . Nedosiran is a GalNAc-dsRNA conjugate[1][2][3].

• Product Name Alternative :

  DCR-PHXC

• UNSPSC :

  12352208

• Target :

  Lactate Dehydrogenase; Small Interfering RNA (siRNA)

• Type :

  Oligonucleotides

• Related Pathways :

  Epigenetics; Metabolic Enzyme/Protease

• Applications :

  Metabolism-protein/nucleotide metabolism

• Field of Research :

  Metabolic Disease

• Assay Protocol :

  https://www.medchemexpress.com/nedosiran.html

• Solubility :

  10 mM in H2O

• Smiles :

  [Nedosiran]

• Molecular Formula :

  C662H865F19N231O413P57S6

• Molecular Weight :

  20985.12

• References & Citations :

  [1]Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.|[2]Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6 (4) :1088-1098. |[3]Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Oligonucleotides

• Clinical Information :

  Launched

• CAS Number :

  [2266591-83-5]